Shigeo Fuji1, Hermann Einsele, Markus Kapp. 1. aDepartment of Hematology, Osaka International Cancer Institute, Osaka, Japan bDivision of Hematology/Oncology, Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
Abstract
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become one of the standard treatment for hematological diseases. Although the clinical outcome has improved significantly during the last decades, the morbidity and mortality after allo-HSCT are still obstacles to cure. Out of major morbidities, opportunistic virus infections such as cytomegalovirus (CMV) infection are important complications, in particular in patients who received human leukocyte antigen-mismatched HSCT. Here, we aim to summarize information about current and future therapeutic options in CMV disease after allo-HSCT. RECENT FINDINGS: Recently, not only new drugs but also adoptive T-cell therapy are tested in the setting of clinical trials. CMV prophylaxis using letermovir significantly reduced the incidence of CMV disease in comparison to placebo in a phase III clinical trial. Meanwhile, adoptive T-cell therapies which are fully adapted to good manufacturing practice (GMP) conditions are now available. A recent multicenter study in Germany showed a promising result using Streptamer-isolated T-cell therapy. SUMMARY: With the recent development of CMV-targeted therapy, treatment strategies of CMV infection would be further sophisticated in the near future. VIDEO ABSTRACT: http://links.lww.com/COID/A19.
PURPOSE OF REVIEW: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become one of the standard treatment for hematological diseases. Although the clinical outcome has improved significantly during the last decades, the morbidity and mortality after allo-HSCT are still obstacles to cure. Out of major morbidities, opportunistic virus infections such as cytomegalovirus (CMV) infection are important complications, in particular in patients who received human leukocyte antigen-mismatched HSCT. Here, we aim to summarize information about current and future therapeutic options in CMV disease after allo-HSCT. RECENT FINDINGS: Recently, not only new drugs but also adoptive T-cell therapy are tested in the setting of clinical trials. CMV prophylaxis using letermovir significantly reduced the incidence of CMV disease in comparison to placebo in a phase III clinical trial. Meanwhile, adoptive T-cell therapies which are fully adapted to good manufacturing practice (GMP) conditions are now available. A recent multicenter study in Germany showed a promising result using Streptamer-isolated T-cell therapy. SUMMARY: With the recent development of CMV-targeted therapy, treatment strategies of CMV infection would be further sophisticated in the near future. VIDEO ABSTRACT: http://links.lww.com/COID/A19.
Authors: Valentina Voigt; Christopher E Andoniou; Iona S Schuster; Anna Oszmiana; Monique L Ong; Peter Fleming; John V Forrester; Mariapia A Degli-Esposti Journal: PLoS Pathog Date: 2018-05-31 Impact factor: 6.823
Authors: Sebastian J Theobald; Sahamoddin Khailaie; Michael Meyer-Hermann; Valery Volk; Henning Olbrich; Simon Danisch; Laura Gerasch; Andreas Schneider; Christian Sinzger; Dirk Schaudien; Stefan Lienenklaus; Peggy Riese; Carlos A Guzman; Constanca Figueiredo; Constantin von Kaisenberg; Loukia M Spineli; Stephanie Glaesener; Almut Meyer-Bahlburg; Arnold Ganser; Michael Schmitt; Michael Mach; Martin Messerle; Renata Stripecke Journal: Front Immunol Date: 2018-11-22 Impact factor: 7.561
Authors: Joseph A Combs; Chandler H Monk; Mark A A Harrison; Elizabeth B Norton; Cindy A Morris; Deborah E Sullivan; Kevin J Zwezdaryk Journal: Antiviral Res Date: 2021-08-11 Impact factor: 5.970
Authors: Kyoung Hwa Lee; Beom Jin Lim; Victor H Ferreira; Seo Yeon Min; Yeon-Mi Hong; Jeong-Hyeon Jo; Sang Hoon Han Journal: Biosci Rep Date: 2018-12-07 Impact factor: 3.840